- Details
- Emmanuel Antonarakis joins Charles Ryan highlighting the first randomized study to assess high-dose testosterone as a treatment for metastatic castration-resistant prostate cancer (mCRPC). TRANSFORMER (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance) was led by Dr. Samuel R. Denmeade at Johns Hopkins School of Medicine – Sidney Kim...
|
- Details
- The presence of mutations in DNA damage repair (DDR) genes has been found in up to 30% of men with metastatic castration-resistant prostate cancer (mCRPC). The CARD trial (Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer) where cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling–targeted inhibitor (abiraterone or enz...
|
- Details
- Unequivocal clinical progression (UPC), a worsening of clinical status with or without radiographic progression represents a distinct mode of disease progression in metastatic prostate cancer. It is prognostic and associated with inferior overall survival and post-progression survival. In this conversation with Alicia Morgans, MD, MPH, Arpit Rao, MD highlights rigorous data set from the phase III...
|
- Details
- Real-world data on the use, survival impacts and efficacy of life-prolonging therapies for metastatic castration-resistant prostate cancer (mCRPC) are limited. In this conversation with Alicia Morgans, MD, MPH, Celestia Higano, MD highlights the publication Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in...
|
- Details
- Wassim Abida, MD, PhD, and colleagues presented an abstract titled, "Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC)" at the 2021 ASCO GU Cancers Symposium. Dr. Wasim Abida joins Charles Ryan, MD highlighting the data that was presented, providing further insight...
|
- Details
- The University of Minnesota has recently launched the CASPAR randomized Phase III clinical trial of enzalutamide and rucaparib versus enzalutamide and placebo in first-line metastatic castrate-resistant prostate cancer (CRPC). Alicia Morgans is joined by Arpit Rao from the Univesity of Minnesota to discuss the launch and the initial success of this new trial. Biographies: Arpit Rao, MD, MBBS, Assi...
|
- Details
- Metastatic castration-resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, an androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in the treatment of advanced pr...
|
- Details
- The field of advanced prostate cancer has rapidly progressed. Prior to the publication of TAX-327, in 2004 there were no proven life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time there have been many new agents that have proven survival benefits including taxane-based chemotherapy, agents targeting the androgen axis, and bone-target...
|
- Details
- Arpit Rao joins Alicia Morgans to discuss the Phase I RAMP trial, looking at the combination of enzalutamide and rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Preclinical studies have demonstrated potential synthetic lethality between androgen receptor signaling inhibition and PARP inhibition, which led to the investigation of these two drugs in combination. The RAMP study...
|
- Details
- In this Journal Club video presentation, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD describe a Clinical Genitourinary Cancer publication Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. The primary objective of this analysis is to describe real-world treatment patterns, includ...
|
